| Abstract | CILJEVI ISTRAŽIVANJA: Ciljevi su bili ispitati povezanost serološkog profila autoimunih
protutijela s kliničkim obilježjima i ishodima bolesti u bolesnika s IIM-om te važnost MSA u
postavljanju dijagnoze, zatim ispitati pojavnost malignih bolesti u bolesnika s IIM-om te utjecaj
terapije na tijek i ishod bolesti.
NACRT STUDIJE: Presječna studija s povijesnim podacima.
MATERIJAL I METODE: Ispitanici istraživanja su pacijenti obaju spolova i svih dobnih
skupina, oboljeli od IIM-a, koji su u razdoblju od 1. siječnja 2017. do 31. prosinca 2021. godine
liječeni na Odjelu za reumatologiju, kliničku imunologiju i alergologiju u KBCO. Podatci su
prikupljeni pregledom podataka o pacijentima u BIS-u. Zabilježena je dob i spol pacijenata, podatci
o dijagnostičkim parametrima (CK, mioglobin, MSA, MAA), podatci o zahvaćenim organima i
organskim sustavima te malignitetima uz miozitis.
REZULTATI: Od ukupno 28 pacijenata s IIM-om, 71,43 % je ženskih, a 28,57 % muških
pacijenata. Aritmetička sredina dobi svih pacijenata je 60,9 (SD = 13,9), u rasponu od 24 do 78
godina. Većina pacijenata je uz miozitis imala pridružene bolesti ili zahvaćene organske sustave
(hipertenzija, zahvaćenost kože i koštano-zglobnog sustava). Pacijenti s pozitivnim Anti-Jo-1
protutijelom imali su zahvaćeno 0 – 4, dok su oni s pozitivnima ostalim protutijelima (ENA screen)
imali zahvaćeno 4 – 9 organa. U 39,3 % pacijenata, 21,4 % ih je dijagnosticirano s malignom, a
17,9 % s benignom bolešću. 17 pacijenata je trenutno u remisiji, 10 pacijenata je postiglo remisiju
uz srednje visoku dozu glukokortikoida.
ZAKLJUČAK: Postoji povezanost između serološkog profila autoimunih protutijela s kliničkim
obilježjima i ishodima bolesti u bolesnika s IIM-om. Pacijenti s dijagnosticiranim IIM-om mogu
imati povećan rizik za maligne bolesti. Svi pacijenti liječeni su glukokortikoidnom terapijom te
nije utvrđena statistički značajna razlika doze glukokortikoida na tijek i ishod bolesti u bolesnika s
IIM-om. |
| Abstract (english) | OBJECTIVES: The objectives were to examine the association of the serological profile of
autoimmune antibodies with the clinical features and outcomes of the disease in patients with IIM,
the importance of MSA in establishing the diagnosis, then to examine the occurrence of malignant
diseases in patients with IIM and the effect of therapy on the course and outcome of the disease.
STUDY DESIGN: Cross-sectional study with historical data.
MATERIAL AND METHODS: The research subjects are patients of both sexes and all age
groups, suffering from IIM, who were treated in the period from January 1, 2017 to December 31,
2021 at the Department of Rheumatology, Clinical Immunology and Allergology at KBCO. Data
were collected by reviewing patient data in the BIS. The age and gender of the patients, data on
diagnostic parameters (CK, myoglobin, MSA, MAA), data on affected organs and organ systems,
and malignancies associated with myositis were recorded.
RESULTS: Out of a total of 28 patients with IIM, 71,43 % were female and 28,57 % were male.
Arithmetic mean age of all patients is 60,9 (SD = 13,9), ranging from 24 to 78 years. In addition to
myositis, the majority of patients had associated diseases or affected organ systems (hypertension,
involvement of the skin and bone-joint system). Patients with a positive Anti-Jo-1 antibody had 0
– 4 organs affected, while those with positive other antibodies (ENA screen) had 4 – 9 organs
affected. In 39,3 % of patients, 21,4 % were diagnosed with malignant and 17,9 % with benign
disease. 17 patients are currently in remission, 10 patients achieved remission with a medium high
dose of glucocorticoids.
CONCLUSION: There is an association between the serological profile of autoimmune antibodies
with clinical features and disease outcomes in patients with IIM. Patients diagnosed with IIM may
have an increased risk for malignancies. All patients were treated with glucocorticoid therapy, and
no statistically significant difference in the dose of glucocorticoid was found on the course and
outcome of the disease in patients with IIM. |
